CD8A and melanoma: Thus, in advanced melanoma, there is a correlation between presence of intratumoral CD8+ T cells and response to Pembrolizumab[62], confirming the need for a preliminary presence of peritumoral CD8+ T-cells together with the inhibitory response of the PD-1/PD-L1 axis as requirements for a potent antitumor response.